Clinical Trial Detail

NCT ID NCT01947023
Title Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

thyroid gland cancer

Therapies

Dabrafenib + Lapatinib

Age Groups: adult senior

Additional content available in CKB BOOST